Pancreatic Progenitor Cell Advancement for Diabetes

Published 2023-11-11

Researchers from the University of Alberta, Canada recently published their findings of an advancement in the use of Stem Cells for Diabetes in the journal Stem Cell Reports. A common limitation of the production of pancreatic progenitor cells is the efficiency of cell conversion coupled with potential immune recognition of allogeneic cells. The research team used autologous induced Pluripotent Stem Cells and added AKT/P70 inhibitor AT7867, an anti-tumor drug. This addition appeard to have increased the efficiency of the production of pancreatic progenitor cells. When used in an in-vivo mouse model, the cells created with the new process led to insulin injection-free glucose control in half the time when transplanted.